A Chinese medicine composition for preventing or treating polycystic ovary syndrome

Abstract

The invention provides a Chinese medicine composition, which comprises the following components by weight: 3-5 parts of bupleurum, 1-3 parts of white wormwood, 1-3 parts of scutellaria, 1-3 parts of liquorice, 1-3 parts of codonopsis, 1-3 parts of white ginger, 1-3 parts of jujube, 1-3 parts of cassia twig, 1-3 parts of angelica, 1-3 parts of ligusticum, 1-3 parts of chuanxiong, 1-3 parts of white peony root, 3-5 parts of wolfberry, 3-5 parts of curculigo, and 3-5 parts of dodder seed. The Chinese medicine composition provided by the invention has a good therapeutic effect on polycystic ovary syndrome.

Description

Technical Field

[0001] The invention belongs to the field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for preventing or treating polycystic ovary syndrome. Background Art

[0002] Polycystic ovary syndrome (PCOS) is a common female reproductive, endocrine and metabolic disease with an incidence of 5%-10% in young women. Its clinical manifestations are diverse, such as amenorrhea, obesity and infertility. Due to the high heterogeneity of its clinical manifestations, its pathogenesis is still unclear and the diagnostic criteria are still controversial. PCOS treatment includes lifestyle adjustment and improvement of metabolic disorders, hyperandrogenemia and reproductive abnormalities. There is currently no effective treatment for PCOS, which has seriously threatened the health of adolescents and women of childbearing age. Therefore, there is an urgent need to explore new therapeutic strategies for the treatment of PCOS.

[0003] Traditional Chinese medicine has accumulated rich clinical experience in the treatment of PCOS, showing great therapeutic value and scientific research potential.

[0004] Chinese patent 202110619720.6 discloses a Chinese medicine composition for treating polycystic ovary syndrome, and its preparation method and use. A Chinese medicine composition is provided, including cinnamon, epimedium, aconite, evodia rutaecarpa, smilax glabra, fritillaria thunbergii, zedoaria, liujiu, safflower, salvia miltiorrhiza, fenugreek and costusroot. The Chinese medicine composition is moxibustioned on the above-mentioned acupoints by the above-mentioned 12 Chinese medicines, that is, by promoting the absorption of the effective ingredients of these drugs by the skin tissue of the acupoints with the help of the heat of moxibustion fire, so as to achieve the effects of warming yang and benefiting the kidney, resolving phlegm and dampness, promoting blood circulation and removing blood stasis, and reducing swelling and dispersing nodules, and can effectively treat polycystic ovary syndrome of kidney deficiency and phlegm and dampness type and kidney deficiency and phlegm and stasis type. However, the implementation of this method requires the help of moxibustion fire, which requires high technical requirements for doctors.

[0005] Chinese patent 202010380045.1 discloses a Chinese medicine soup for treating infertility caused by polycystic ovary syndrome with kidney deficiency and phlegm dampness, which can effectively solve the problem of medication for infertility caused by polycystic ovary syndrome with kidney deficiency and phlegm dampness. The soup is made of 15-20g of Eucommia ulmoides, 20-30g of Cuscuta australis, 10-15g of stir-fried Atractylodes macrocephala, 10-15g of Atractylodes macrocephala, 10-15g of Pinellia ternata, 10-20g of Poria, 10-15g of Cyperus rotundus, 10-15g of dried tangerine peel and 3-6g of cinnamon twig, wherein the above-mentioned drugs are added with 400-600mL of water and simmered at 18-25℃ The invention is rich in raw materials, simple in preparation method, low in cost, easy to take, and effective in treating kidney-warming and pregnancy-assisting, regulating qi and resolving phlegm, and is an innovation in treating infertility caused by polycystic ovary syndrome with kidney deficiency and phlegm-dampness. However, its effective rate measurement standard is low, and its efficacy needs to be verified.

[0006] There is still a need for a better Chinese medicine composition to treat polycystic ovary syndrome. Summary of the invention

[0007] In order to solve the above problems, the present invention provides a Chinese medicine composition, which has a better therapeutic effect on PCOS through scientific compatibility.

[0008] In one aspect, the present invention provides a traditional Chinese medicine composition.

[0009] The Chinese medicine composition comprises the following components by weight:

[0010] 3-5 parts of bupleurum, 1-3 parts of artemisia annua, 1-3 parts of scutellaria baicalensis, 1-3 parts of licorice, 1-3 parts of codonopsis pilosula, 1-3 parts of white ginger, 1-3 parts of jujube, 1-3 parts of cinnamon twig, 1-3 parts of angelica, 1-3 parts of chuanxiong, 1-3 parts of white peony root, 3-5 parts of wolfberry, 3-5 parts of curculigo, and 3-5 parts of dodder seed.

[0011] Preferably, the Chinese medicine composition comprises the following ingredients by weight: 3-5 parts of bupleurum, 2 parts of artemisia annua, 1-3 parts of scutellaria baicalensis, 1-3 parts of licorice, 1-3 parts of codonopsis pilosula, 1-3 parts of white ginger, 1-3 parts of jujube, 2 parts of cinnamon twig, 1-3 parts of angelica, 1-3 parts of chuanxiong, 1-3 parts of white peony root, 3-5 parts of wolfberry, 4 parts of curculigo, and 3-5 parts of dodder seed.

[0012] Further preferably, the Chinese medicine composition comprises the following ingredients by weight: 4 parts of bupleurum, 2 parts of artemisia annua, 2 parts of scutellaria baicalensis, 2 parts of licorice, 2 parts of codonopsis pilosula, 2 parts of white ginger, 2 parts of jujube, 2 parts of cinnamon twig, 2 parts of angelica, 2 parts of ligusticum, 2 parts of chuanxiong, 2 parts of white peony root, 4 parts of wolfberry, 4 parts of curculigo, and 4 parts of dodder seed.

[0013] The Chinese medicinal name of Bupleurum is Bupleurum, the Chinese medicinal name of Artemisia annua is Pinellia, the Chinese medicinal name of Scutellaria baicalensis is Scutellaria baicalensis, the Chinese medicinal name of Licorice is Licorice, the Chinese medicinal name of Codonopsis pilosula is Codonopsis pilosula, the Chinese medicinal name of white ginger is Ginger, the Chinese medicinal name of jujube is Jujube, the Chinese medicinal name of cinnamon twig is cinnamon twig, the Chinese medicinal name of Angelica sinensis is Angelica sinensis, the Chinese medicinal name of Chuanxiong is Chuanxiong, the Chinese medicinal name of white peony root is white peony root, the Chinese medicinal name of Lycium barbarum is Cnidium monnieri, the Chinese medicinal name of Curculigo orchioides is Xiaomao, and the Chinese medicinal name of Cuscuta australis is Tusizi.

[0014] On the other hand, the present invention provides use of the aforementioned Chinese medicine composition in the preparation of a medicament for preventing or treating polycystic ovary syndrome.

[0015] The medicine includes the aforementioned Chinese medicine composition or its extract.

[0016] In yet another aspect, the present invention provides a method for preparing a drug for treating polycystic ovary syndrome.

[0017] The preparation method uses the aforementioned Chinese medicine composition as raw material for preparation.

[0018] The preparation method comprises boiling the aforementioned traditional Chinese medicine composition.

[0019] Preferably, 20 g of medicinal liquid is obtained after boiling.

[0020] The preparation method may also include other commonly used pharmaceutical technologies.

[0021] In yet another aspect, the present invention provides a medicament for preventing or treating polycystic ovary syndrome.

[0022] The medicine includes the aforementioned Chinese medicine composition or its extract.

[0023] The extracts include but are not limited to water extracts.

[0024] The dosage forms of the drug include but are not limited to: decoction, tablets, syrup, granules, oral liquid, and pills.

[0025] The medicine also includes other pharmaceutically acceptable carriers or excipients. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The results of the glucose tolerance test in Example 1.

[0027] Figure 2This is the detection result of AKT mRNA expression in Example 1.

[0028] Figure 3 This is the detection result of PI3K mRNA expression in Example 1.

[0029] Figure 4 This is a photo of the ovarian morphology of the treatment group in Example 1 with an optical magnification of 100 times, HE staining.

[0030] Figure 5 This is a 40-fold optical magnification photograph of the ovarian morphology of the control group in Example 1, HE staining.

[0031] Figure 6 This is a HE-stained photo of the ovary morphology of the control group in Example 1 at 100 times optical magnification.

[0032] Figure 7 This is the differential gene map of Example 1 (A is the differential gene heat map; B is the differential gene volcano map).

[0033] Figure 8 This is the differential miRNA analysis of the whole transcriptome sequencing in Example 1. DETAILED DESCRIPTION

[0034] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0035] In the embodiment:

[0036] 24-day-old SPF female Sprague-Dawley rats weighing 250-300 g were obtained from the Experimental Animal Center of Guangxi Medical University (Nanning, China). Animal production license number: SCXK (Gui) 2020-0003. All rats were housed in the SPF animal room of the Guangxi University of Chinese Medicine laboratory, using standard water, rat food and standard environment (temperature 25 ± 2 °C, relative humidity 60 ± 5%, 12 h light-dark cycle).

[0037] The original drugs were purchased from Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd. (Beijing, China). The decoction plus the concentrated Chinese medicine granules totaled 20 g.

[0038] Levonorgestrel capsules, specification: 75 mg, purchased from Shanghai Dahua Pharmaceutical Co., Ltd., batch number YZ20190103;

[0039] Human chorionic gonadotropin was purchased from Livzon Pharmaceutical Factory, approval number 200805;

[0040] The reverse transcription kit was purchased from Novo Protein Technology Co., Ltd., batch number 0519281;

[0041] Fluorescence quantitative PCR kit (SYBR Green Master Mix) was purchased from Zhuoyi Biotechnology Co., Ltd., batch number A25742;

[0042] Primers were synthesized by Shanghai Shenggong Bioengineering Co., Ltd.;

[0043] The electric tissue grinder was purchased from Tiangen Biochemical Technology Co., Ltd. (Beijing, model: OSE-Y30);

[0044] Centrifuge model: Stratos, Thermo Fisher Scientific;

[0045] PCR gene amplifier, model: 3200, Zhuhai Haima Medical Instrument Co., Ltd.;

[0046] Handheld centrifuge: Haimen Kelly Bell Laboratory Instrument Co., Ltd., model: LX-100;

[0047] Real-time fluorescence quantitative PCR (qRT-PCR), model: 7500, Applied Biosystems;

[0048] The blood glucose meter and blood glucose test strips were purchased from One Touch UltraEasy.

[0049] Example 1

[0050] The formula of the Chinese medicine composition in this embodiment is as follows:

[0051] 20 grams of bupleurum, 10 grams of artemisia annua, 10 grams of scutellaria baicalensis, 10 grams of licorice, 10 grams of codonopsis pilosula, 5 grams of white ginger, 5 grams of jujube, 10 grams of cinnamon twig, 10 grams of angelica, 10 grams of chuanxiong, 10 grams of white peony root, 20 grams of wolfberry, 20 grams of curculigo, and 20 grams of dodder seed.

[0052] The above composition is boiled with water for 30-60 minutes to prepare 20g of Chinese medicine decoction.

[0053] After 3 days of adaptive feeding, 30 rats were randomly divided into a control group (n=6), a PCOS group (n=12), and a treatment group (n=12). Progesterone combined with HCG was used to establish a rat model of polycystic ovary syndrome. Rats in the PCOS group and the treatment group were subcutaneously implanted with levonorgestrel rods (3-4 mm), and 3 days later, chorionic gonadotropin (3 U added to 0.1 mL of normal saline) was injected for 9 consecutive days to establish the PCOS model. The sham operation group was injected with an equal amount of normal saline. The treatment group received 4200 mg / kg / d of Chinese herbal decoction, while the control group and PCOS model group received an equal amount of distilled water.

[0054] (1) Blood sugar test:

[0055] OGTT (Oral Glucose Tolerance Test) was performed after fasting for 12 hours in three groups of rats. Rats had free access to water. Tail blood was collected and serum glucose levels were measured using OneTouch UltraEasy blood glucose meter and blood glucose test strips. Using oral gavage, rats received 50% glucose (2 g glucose / kg). Serum glucose levels were then measured after 30 minutes, 60 minutes, and 120 minutes.

[0056] ITT (Insulin Tolerance Test) The three groups of rats were fasted for 4 hours and had free access to water. The glucose level in the blood collected from the tail was determined using the OneTouchUltraEasy blood glucose meter and blood glucose test strips. The rats were then intraperitoneally injected with insulin at 0.5 / kg, and the blood glucose level was measured in the tail after 30 minutes, 60 minutes, 90 minutes and 120 minutes.

[0057] (2) HE staining

[0058] The method comprises the following steps: the ovarian tissue is fixed and immersed in 4% formalin solution for examination, placed on a tissue embedding tray, the tissue block is embedded with OCT glue and cut into pieces with a slicer having a thickness of about 4 μm, placed on a glass slide, stained with hematoxylin, stained with eosin after blueing, and observed under a 10x eyepiece and a 10-100x light microscope.

[0059] (3) Detection of gene expression

[0060] Total RNA was extracted from mouse ovarian tissue using the TRIzol method. A reverse transcription cDNA kit was used with the following reaction conditions: 42°C, 5 minutes; 50°C, 15 minutes; 75°C, 5 minutes. Rat GAPDH was used as an internal control gene. Primers were added. The following amplification conditions were used for qRT-PCR: 94°C, 1 minute; 94°C, 20 seconds, 57°C, 20 seconds, 72°C, 60 seconds / 1kb, 30 cycles; 72°C, 5 minutes. The Ct value of the qPCR fluorescence curve was determined. ΔCt = target gene Ct value - GAPDH Ct value.

[0061] The quantitative PCR primer sequences are shown below:

[0062]

[0063] (4) Whole transcriptome sequencing

[0064] RNA was extracted from rat ovarian tissue using TRIzol reagent, and DNA was digested using DNaseI. RNA was detected using Qubit3.0 with QubitTM RNA Broad Range Assay Kit. 2 μg of total RNA was used for RNA sequencing library preparation using Ribo-off rRNA DepletionKit and KCTM Stranded mRNA Library Prep Kit. The library products corresponding to 200-500 bp were enriched and quantified, and finally sequenced using the DNBSEQ-T7 sequencer using the PE150 mode.

[0065] RNA-Seq data analysis The raw sequencing data were first filtered by Trimmomatic (version 0.36), and the clean reads were mapped to the rat reference genome using the default parameters of STRA software (version 2.5.3a). The reads mapped to the exonic region of each gene were counted by featureCounts (Subread-1.5.1; Bioconductor), and then RPKM was calculated. The edgeR package (version 3.12.1) was used to identify differentially expressed genes between groups. The p-value cutoff 0.05 and fold-change cutoff 2 were judged as statistically significant for differential expression of genes. GO analysis and KEGG enrichment analysis of differentially expressed genes were performed by KOBAS software (version: 2.1.1), with a p-value threshold of 0.05 to judge statistically significant enrichment. rMATS (version 3.2.5) was used to detect alternative splicing events, with an FDR value cutoff of 0.05 and a Δψ absolute value of 0.05.

[0066] LncRNA analysis. New lncRNAs were predicted by lncRNA analysis. The expression of new lncRNAs and known lncRNAs annotated by the genome was counted by featureCounts (Subread-1.5.1; Bioconductor), and then RPKM was calculated. The edgeR package (version 3.12.1) was used to identify the differentially expressed lncRNAs between the groups. P value cutoff 0.05 and fold-change cutoff 2 were used to judge the statistical significance of the difference in lncRNA expression. The target genes of differentially expressed lncRNAs were predicted. GO analysis and KEGG enrichment analysis of differentially expressed genes were performed by KOBAS software (version: 2.1.1), with a p value threshold of 0.05 to judge statistically significant enrichment.

[0067] (5) miRNA sequencing and data analysis

[0068] RNA was extracted from rat ovarian tissue using TRIzol reagent, and miRNA library was constructed using KC-DigitTM small RNALibrary Prep Kit for Illumina kit, and pre-amplified miRNA molecules were labeled with unique molecular identifiers (UMI). The eluted cDNA library was separated using 6% PAGE gel electrophoresis. After the band of about 160 bp was separated, it was separated, purified and quantified by Qubit 3.0, and finally sequenced using HiSeq X-10 sequencer (Illumina) sequencer using PE150 template.

[0069] The raw sequencing data were first screened by fastx_toolkit (version: 0.0.13.2), and the consensus sequences were mapped to the reference genome of rats using bowtie software (version: 1.1.2). The package was used to map the reads to known primary miRNAs in the miRBase database and predict new miRNAs. The edgeR package (version: 3.12.1) was used to determine the differences in miRNA expression between groups. The thresholds of P < 0.05 and |Log2Fold-change| > 1 were used to determine whether the differences in miRNA expression were statistically significant. miRanda v3.3a software was used to predict the target mRNAs of differentially expressed miRNAs. KOBAS software (version: 2.1.1) was used to perform GO and KEGG enrichment analysis on the predicted target mRNAs, and P < 0.05 was judged to be statistically significant. The miRNA-mRNA co-expression network was constructed by WGCNA (version 1.61), and the correlation threshold between miRNA and mRNA was > 0.8.

[0070] Results and analysis:

[0071] (1) In the insulin tolerance test, the blood glucose levels in the control group and the treatment group were significantly lower than those in the PCOS group (P<0.05); however, the difference in serum glucose between the control group and the treatment group was not significant. In the glucose tolerance test, there was no significant difference in blood glucose levels among the three groups (P>0.05). Figure 1 shown.

[0072] (2) Compared with the PCOS rat model, the blood glucose level of the PCOS treatment group was significantly improved by the intervention of the drug of the present application, indicating that the drug may have a therapeutic effect on PCOS by regulating glucose metabolism.

[0073] (3) Ovarian morphology HE staining showed that after drug intervention, multiple dilated follicles coexisted with follicles at multiple developmental stages in PCOS rats. The follicle structures at all levels were normal, and structures such as oocytes, cumulus ovaries, and corona radiata were visible in the follicles. The corpus luteum was present. In contrast, the ovarian capsule of the control group was thickened, and multiple cystic dilated follicles were visible in the ovaries. The number of loose layers of oocytes and the loss of corona granulosa cells were reduced in the PCOS rat model. Figure 4-6 . Figure 4 This is the ovarian morphology of the treatment group. The optical magnification is 100 times. Follicles at various developmental stages, mature oocytes and corpus luteum can be seen under the microscope. The granulosa cell layer is arranged regularly. Figure 5 At 40 times the magnification of the control group, multiple follicles at the same developmental stage were seen, and the follicles were cystically dilated. Figure 6 The granulosa cell layer of the follicles was loosely arranged at 100 times the magnification of the control group.

[0074] (3) AKT mRNA expression results are as follows Figure 2 As shown, the results showed that based on the AKT gene expression level of normal rats, the expression level of polycystic ovary rats was 1.05, and the expression level of polycystic ovary rats in the Chinese medicine group was 1.04, with no significant difference.

[0075] (4) PI3K mRNA expression results are as follows Figure 3 As shown, the results showed that: based on the PI3K gene expression level of normal rats, the expression level of polycystic ovary rats was 1.43, and the expression level of polycystic ovary rats in the Chinese medicine group was 1.19, which was lower than that of polycystic ovary rats in the control group.

[0076] (5) Whole transcriptome sequencing of ovarian tissue for differential gene analysis ( Figure 7 ), the results showed that there were 189 differentially expressed genes between the Chinese medicine group and the PCOS model group, including 48 up-regulated genes and 141 down-regulated genes. GO biological process analysis showed that the down-regulated genes were enriched in the metabolism of organic hydroxyl compounds, the response to hormones, the alcohol metabolism process, lipid transport, etc., and the up-regulated genes were enriched in the cell response to organic matter, the response to organic matter, the response to oxygen-containing compounds, etc. KEGG analysis showed that the up-regulated genes were enriched in the PI3K-Akt, Metabolic, Jak-STAT and other signal pathways, and the down-regulated genes were enriched in the Metabolic, PPAR and other signal pathways. The results of GO analysis and KEGG signal pathway enrichment analysis showed that in the PI3K / Akt signal pathway, the Chinese medicine composition in this embodiment played an important role in intervening PCOS. The intervention of the Chinese medicine composition in this embodiment on PCOS was related to the regulation of the PI3K / Akt signal pathway.

[0077] (6) Differential miRNA analysis: Differential miRNAs were found between the treatment group and the PCOS group, with 4 upregulated miRNAs and 4 downregulated miRNAs. miR-206-3p and other ceRNAs involved in network regulation were also found to be related to the intervention of the treatment group. Figure 8 A), whole transcriptome sequencing analysis miRNA heat map analysis ( Figure 8 B). The results showed that miR-206-3p played an important role in the intervention of PCOS in the treatment group, and previous studies have shown that miR-206-3p may play an important role in the pathogenesis of PCOS.

[0078] Comparative Example

[0079] A comparative example was set up with reference to the treatment group of Example 1, and the medication components were as follows:

[0080] The difference in medication between the treatment group and Example 1 Comparative Example 1 No Curculigo added Comparative Example 2 No added cinnamon Comparative Example 3 No Artemisia selengensis added Comparative Example 4 No Curculigo and Cinnamon Twigs Comparative Example 5 No Curculigo and Artemisia argyi added Comparative Example 6 No cinnamon twig and white wormwood added

[0081] The PI3K mRNA expression was detected, and the PI3K mRNA expression of normal rats was used as a benchmark. The results are as follows:

[0082]

[0083] Sequence Listing <110> Beijing Sanyi Wisdom Technology Co., Ltd. <120> A Chinese medicine composition for preventing or treating polycystic ovary syndrome <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <400> 1 gacatgccgc ctggagaaac 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <400> 2 agcccaggat gccctttagt 20 <210> 3 <211> 19 <212> DNA <213> Artificial Sequence <400> 3 ctacctcgcc gttcctgtg 19 <210> 4 <211> twenty one <212> DNA <213> Artificial Sequence <400> 4 ttgacctgac ccatctgacc t 21 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <400> 5 aggcatccct tccttacagc 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <400> 6 cagcccgaag tccgttatct 20

Claims

1. A Chinese medicine composition, characterized in that: The composition is calculated by weight: 3-5 parts of bupleurum, 1-3 parts of artemisia annua, 1-3 parts of scutellaria baicalensis, 1-3 parts of licorice, 1-3 parts of codonopsis pilosula, 1-3 parts of white ginger, 1-3 parts of jujube, 1-3 parts of cinnamon twig, 1-3 parts of angelica, 1-3 parts of chuanxiong, 1-3 parts of white peony root, 3-5 parts of wolfberry, 3-5 parts of curculigo, and 3-5 parts of dodder seed.

2. The Chinese medicine composition according to claim 1, characterized in that: The invention is composed of the following ingredients by weight: 3-5 parts of bupleurum, 2 parts of artemisia annua, 1-3 parts of scutellaria baicalensis, 1-3 parts of liquorice, 1-3 parts of codonopsis pilosula, 1-3 parts of white ginger, 1-3 parts of jujube, 2 parts of cinnamon twig, 1-3 parts of angelica, 1-3 parts of ligusticum, 1-3 parts of ligusticum chuanxiong, 1-3 parts of white peony root, 3-5 parts of wolfberry, 4 parts of curculigo orchioides, and 3-5 parts of dodder seed.

3. The Chinese medicine composition according to claim 1, characterized in that The composition is composed of the following ingredients by weight: 4 parts of bupleurum, 2 parts of artemisia annua, 2 parts of scutellaria baicalensis, 2 parts of liquorice, 2 parts of codonopsis pilosula, 2 parts of white ginger, 2 parts of jujube, 2 parts of cinnamon twig, 2 parts of angelica, 2 parts of ligusticum, 2 parts of ligusticum, 2 parts of white peony root, 4 parts of wolfberry, 4 parts of curculigo, and 4 parts of dodder seed.

4. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of a medicament for preventing or treating polycystic ovary syndrome.

5. The use according to claim 4, characterized in that: The medicine is the Chinese medicine composition or its extract according to any one of claims 1 to 3.

6. A method for preparing a drug for treating polycystic ovary syndrome, characterized in that: The preparation is carried out using the Chinese medicine composition described in claim 1 as a raw material.

7. The preparation method according to claim 6, characterized in that: include: The Chinese medicine composition according to any one of claims 1 to 3 is prepared by boiling.

8. A drug for preventing or treating polycystic ovary syndrome, characterized in that: The medicine is the Chinese medicine composition or its extract according to any one of claims 1 to 3.

9. The drug according to claim 8, characterized in that The medicine also includes other pharmaceutically acceptable carriers or excipients.

Images